Evaxion Biotech A/S (EVAX) has a negative trailing P/E of -3.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 103.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -28.99%, forward earnings yield 0.97%. PEG 2.50.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2018 | -42.9 | 0.00 | -254.93 | 0.00 | - |
| 2019 | -17.9 | -0.13 | 21.39 | 0.00 | - |
| 2020 | -13.3 | -0.39 | 28.45 | 0.00 | - |
| 2021 | -4.4 | -0.12 | 3.32 | 0.00 | - |
| 2022 | -2.3 | 0.10 | 6.32 | 0.00 | - |
| 2023 | -1.1 | 0.06 | -4.95 | 320.92 | - |
| 2024 | -0.4 | 0.01 | -2.75 | 1.36 | - |
| 2025 | -4.0 | 0.05 | 1.79 | 4.05 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-2.30 | $0.00 | $-5.54M | - |
| 2019 | $-5.53 | $0.00 | $-11.2M | - |
| 2020 | $-7.42 | $0.00 | $-15.02M | - |
| 2021 | $-10.06 | $0.00 | $-24.53M | - |
| 2022 | $-7.84 | $0.00 | $-23.17M | - |
| 2023 | $-6.49 | $73K | $-22.13M | -30308.2% |
| 2024 | $-2.00 | $3.34M | $-10.57M | -316% |
| 2025 | $-1.21 | $7.55M | $-7.73M | -102.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.03 | $-0.03 – $-0.03 | $5.28M | $5.28M – $5.28M | 1 |
| 2027 | $0.04 | $0.04 – $0.04 | $22.6M | $22.6M – $22.6M | 1 |
| 2028 | $0.01 | $-0.03 – $0.04 | $24.04M | $24.04M – $24.04M | 2 |
| 2029 | $0.08 | $0.08 – $0.08 | $72.65M | $72.65M – $72.65M | 1 |
| 2030 | $-0.01 | $-0.01 – $-0.01 | $29.14M | $29.14M – $29.14M | 1 |
